Daawaynta kansarka beerka, dawooyinka kansarka beerka lala beegsaday, isku darka cusub ee dawooyinka kansarka beerka ayaa si weyn u dheereeya badbaadada.
Qiyaasta kansarka & badbaadada
The number of people that survive for five years after being diagnosed with digestive system cancers seems to be particularly low in India compared to more advanced countries. Survival rates are just 19% for stomach cancer compared to 25-30% in most countries, with 58% surviving in South Korea. In India, the survival rate for kansarka mindhicirka is 37% while it is 50-59% in most countries and goes up to 65% in the US. Only 4% of kansarka beerka patients survive for five years in India compared to 10 to 20% elsewhere. Survival rates have dipped in the case of rectal cancer in India.
Even in breast and kansarka qanjirka 'prostate', where medical advances have ensured that over 80% of patients survive in advanced countries, only about 60% of Indian patients survive. Kansarka qoorta survival rates have declined in India from 23% in 1995-99 to 14% in 2005-09. kansarka ilmo survival rates are 46% compared to the global figure of 50%, but there is a slight decline in India from 47% in 2005. It is understood that there are one million new liver cancer patients worldwide each year, of which 55% are patients in China. About 110,000 people die of liver cancer each year in China, and the 5-year recurrence rate in China is as high as 70%. Liver cancer is highly malignant and highly contagious.
Calaamadaha hore ee kansarka beerka
1. Cough: The liver mass stimulates the diaphragm. During breathing, it causes a reflex in the lungs to cause a cough, or liver cancer has lung metastases that cause a cough.
2. Daal: Unugyada kansarku waxay waxyeeleeyaan shaqada keydinta beerka oo tamarta jirka ayaa yaraata.
3. Miisaanka oo yaraada sabab la’aan: Unugyada kansarku waxay u baahan yihiin tamar iyo nafaqooyin aad iyo aad uga badan unugyada caadiga ah inta lagu jiro geeddi-socodka koritaanka, taasoo keenta nafaqo la’aan ku haysa jirka, sidaa darteed bukaanku waxay muujinayaan culeys kordhaya. Kansarrada kale waxay sidoo kale muujiyaan astaamo qashin.
4. Calaamadaha caloosha: Xanuunada dheefshiidka ayaa dhaca. Qiyaastii saddex-meelood meel bukaanada qaba kansarka beerka waxay la kulmi doonaan astaamaha cudurada mareenka dheef-shiidka marxaladda hore ee jirrada, oo la mid ah cudurrada caloosha.
5. Fever: mostly cancerous fever, which is mainly caused by the release of pyrogens into human blood circulation after buro necrosis unug.
6. Dhiigbax: cirridka oo dhiig baxa, nabarro subcutaneous iyo astaamo kale.
7. Xanuun: Cagaarshow xanuunka waxa uu ku dhacaa badi bukaanada qaba kansarka beerka oo sare u kacay.
Maxay ugu badan yihiin bukaanada kansarka beerka ku jira wadamada soo koraya? Maxay yihiin sababaha kansarka beerka?
1. Khamriga iyo cagaarshow alkolada: Khamriga iyo sunta metabolite acetaldehyde waxay keeni kartaa beerka dufanka leh, cagaarshowga khamriga, iyo xitaa beerka fibrosis iyo kansarka beerka.
2. Cayilka iyo beerka dufanka leh: Cayilku waa mid ka mid ah sababaha keena cudurro badan oo daba-dheeraada. Cayilku waxa uu sababi karaa dhibaatooyin beerka dufanka leh oo uu xataa uga sii daro cirrhosis iyo kansarka beerka. Caadi ahaan, fiiro gaar ah u yeelo 7 dhibcood oo ay ka buuxaan cunto, caadooyin jimicsi oo wanaagsan, cun dufan badan iyo qaab nololeed cunto sonkor badan.
3. Cagaarshowga fayraska ee B/C: Cagaarshowga joogtada ah ee B iyo C waa sababaha ugu waaweyn ee kansarka beerka waagii hore, qiyaastii 60 ~ 70%. Iyadoo si buuxda loo hirgeliyay tallaalka cagaarshow B ee dhallaanka cusub, saamiga infekshanka cagaarshow B ayaa hoos u dhacay. Cagaarshow C sidoo kale aad ayuu caan u ahaa dhowr sano ka hor. Cagaarshowga C hadda waa la daweyn karaa khatarta cagaarshowga fayraska ayaa sii yaraanaya.
Sidee looga hortagaa kansarka beerka inuu soo noqdo?
1. Daaweynta xoojinta firfircoon. Qalliinka iyo daaweynta la xiriirta ayaa ka saari kara inta badan unugyada burooyinka, laakiin unugyada kansarka gabi ahaanba lama saari karo. Unugyada kansarka haraaga waxay leeyihiin ixtimaal sare oo soo noqosho ah; sidaa darteed, daaweynta isku-darka waa in lagu sameeyaa waqti ku habboon. Daawada dhaqameed ee Shiinaha iyo daawooyinka beerka iyo beerka laga ilaaliyo ayaa la isticmaali karaa waqti dheer.
2. Si firfircoon u jimicso si aad u xoojiso xasaanaddaada iyo iska caabbinta cudurka.
3. Cunto isu dheelitiran, xoojiso nafaqada, yareeynta dufanka iyo yareynta neefsiga walxaha sunta ah.
4. Joogtee maskaxda wanaagsan, badiyaa bar inaad hagaajiso maskaxda iyo shucuurta, ku guuleysato isku darka shaqada iyo nasashada, iskana ilaali shaqada badan. Cadaadiska iyo daalku waxay sababi karaan daciifnimo jireed, taasoo u horseedi karta difaac hooseeya iyo difaac hooseeya, oo u horseedi kara kansar.
Sidee loo daweeyaa kansarka beerka maxaase lagu daweeyaa?
Liver cancer treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
Dawooyinka lagu bartilmaameedsado kansarka beerka
| magaca guud | magaca Product | Target | Time in ay suuqa | Shiinaha ayaa ku taxan | Baaraha asalka ah | Nooca daroogada |
| Sorafenib | Nexavar, Dogemi | KIT, VEGFR, PDGFR | 2005 | Haa | Bayer | Molecule yar |
| Regorafenib | Stivarga | Bartilmaameed badan | 2012 | maya | Bayer | Molecule yar |
| Ramucirumab | Cyramza | VEGFR2 | 2014 | Haa | Eli Lilly | MAb |
| Lenvatinib | Lenvima | Bartilmaameed badan | 2015 | Haa | Ciise | Molecule yar |
Isku darka atejizumab iyo bevacizumab ayaa ka wanaagsan daawaynta monotherapy
Recently, the European Society of Oncology 2019 (Asian Congress) held in Singapore announced the phase III of the tumor immunotherapy Tecentriq (atezolizumab, atuzumab) combined with Avastin (bevacizumab) first-line treatment of hepatocellular carcinoma (HCC). Clinical study IMbrave150 (NCT03434379). Compared to sorafenib, the first-line combination of atrezumab and bevacizumab has statistically and clinically improved progression-free survival (PFS) and overall survival (OS). The risk of death was reduced by 42% in patients receiving combination therapy, and the progression-free survival rate was 41% (no progression or risk of death).
In addition, in December 2018, the US FDA approved atezolizumab combined with bevacizumab + chemotherapy (carboplatin and paclitaxel) as first-line treatment for adult patients with metastatic non-squamous kansarka sanbabada ee aan yareyn without EGFR or ALK genome tumor aberrations. Based on data from group B of the IMpower150 study, compared with bevacizumab + chemotherapy, atezolizumab combined with bevacizumab + chemotherapy significantly prolonged patient survival (19.2 months vs 14.7 months).
Atuzumab waa antibody PD-L1 waxaana iska leh buro-daawaynta difaaca. Daroogadu waxay ku xidhmi kartaa borotiinka loo yaqaan PD-L1 ee lagu muujiyay unugyada burooyinka iyo buro soo dhex galeysa unugyada difaaca, kana xannibaya PD-1 iyo B7. .1 dhexgalka reseptor. Iyadoo la joojinayo PD-1, atuzumab waxay kicin kartaa unugyada T, kuwaas oo awood u leh in loo isticmaalo daaweynta aasaasiga ah ee isku-dhafka ah ee difaaca difaaca kansarka, daroogooyinka la beegsaday iyo daaweynta kemotherabi ee kala duwan.
Bevacizumab waa anjiogenesis inhibitor ah oo bartilmaameedsanaya ku xirnaanta cunsurrada koritaanka endothelial (VEGF). VEGF waxay door muhiim ah ka ciyaartaa angiogenesis iyo dayactirka wareegga nolosha burooyinka. Avastin wuxuu ku dhacaa dhiigga soo bixida burooyinka isagoo si toos ah ugu xidhan VEGF, isaga oo ka hortagaya inuu la falgalo qaboojiyeyaasha unugyada xididdada. Dhiig bixinta burada waxaa loo tixgeliyaa inay tahay
fure u ah awooddeeda koritaanka iyo metastasize in vivo.
Waxaa jira aasaas cilmiyaysan oo xoog leh oo la isku daro atelizumab iyo bevacizumab, isku darka labada daawo ayaa leh awood lagu xoojiyo habka difaaca jirka ee burooyinka. Marka lagu daro saameynta anti-angiogenic ee la aasaasay, bevacizumab waxay sii xoojin kartaa atezumab si loo soo celiyo iska caabinta jirka iyadoo la xakameynayo tallaalka la xiriira VEGF, dhiirrigelinta soo-galista burooyinka T-cell, iyo bilaabista jawaabaha T-cell ee burooyinka antigens Difaaca kansarka.
